<DOC>
	<DOCNO>NCT02143973</DOCNO>
	<brief_summary>The primary objective study evaluate overall safety nalbuphine HCL ER tablet treatment period 24 week .</brief_summary>
	<brief_title>Open Label Extension Study Nalbuphine HCl ER Hemodialysis Patients With Uremic Pruritus</brief_title>
	<detailed_description />
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Nalbuphine</mesh_term>
	<criteria>Subject complete participation TR02 study Subject currently receive incenter hemodialysis time consent Subject receiving anticipate receive nocturnal dialysis home hemodialysis treatment study Subject receive opiate daily basis 1 week prior screen Other TR02 Study Drug , Subject receive investigational drug within 4 week prior Screening Subject pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Uremic</keyword>
	<keyword>Pruritus</keyword>
	<keyword>Itch</keyword>
	<keyword>Chronic Itch</keyword>
	<keyword>Nalbuphine</keyword>
</DOC>